GoAI
Get started
TransMedics Group, Inc. logo

TransMedics Group, Inc.

TMDX

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$94.77

+$3.92 · +4.31%

Aug 21, 4:00 PM ET

TMDX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

87

Deep Value

Momentum

25

Weakening

Sentiment

78

Bullish

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Waleed H. Hassanein
Listed since
May 2, 2019
Employees
898

Market position

Day range

Current $94.77

52-week range

Current $94.77

Open
$91.11
Previous close
$90.85
Volume
628.72K
0.52× average
Average volume
1.21M
Average daily volume
Market cap
3.28B USD
Beta
1.88
Market reference 1
50-day average
$77.4672
+22.34% above average
200-day average
$106.31
-10.85% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.12B USD
P/E (TTM)
21.44×
P/B (TTM)
6.33×
P/S (TTM)
4.9×
EV / EBITDA
27.72×
Earnings yield
4.60%
Free cash flow yield
3.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
58.69%
Operating margin
12.21%
Net margin
22.69%
Return on equity
40.22%
Return on assets
17.81%
Return on invested capital
10.94%

Financial health

Debt / equity
1.67×
Current ratio
7.14×
Altman Z-score
2.95
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends92%5%-81%-168%Gross margin, FY2021: 69.92%Gross margin, FY2022: 69.84%Gross margin, FY2023: 63.77%Gross margin, FY2024: 59.36%Gross margin, FY2025: 59.92%Operating margin, FY2021: -130.29%Operating margin, FY2022: -33.64%Operating margin, FY2023: -11.89%Operating margin, FY2024: 8.49%Operating margin, FY2025: 17.93%Net margin, FY2021: -146.11%Net margin, FY2022: -38.77%Net margin, FY2023: -10.36%Net margin, FY2024: 8.03%Net margin, FY2025: 31.43%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 69.92%. Gross margin FY2022 69.84%. Gross margin FY2023 63.77%. Gross margin FY2024 59.36%. Gross margin FY2025 59.92%. Operating margin FY2021 -130.29%. Operating margin FY2022 -33.64%. Operating margin FY2023 -11.89%. Operating margin FY2024 8.49%. Operating margin FY2025 17.93%. Net margin FY2021 -146.11%. Net margin FY2022 -38.77%. Net margin FY2023 -10.36%. Net margin FY2024 8.03%. Net margin FY2025 31.43%.

Income trends

Revenue

605.49M USD+37.13%

Operating income

108.58M USD+189.59%

Net income

190.29M USD+436.58%
Income trends across reported periods670.46M USD410.58M USD150.7M USD−109.19M USDRevenue, FY2021: 30.26M USDRevenue, FY2022: 93.46M USDRevenue, FY2023: 241.62M USDRevenue, FY2024: 441.54M USDRevenue, FY2025: 605.49M USDOperating income, FY2021: −39.43M USDOperating income, FY2022: −31.44M USDOperating income, FY2023: −28.73M USDOperating income, FY2024: 37.5M USDOperating income, FY2025: 108.58M USDNet income, FY2021: −44.22M USDNet income, FY2022: −36.23M USDNet income, FY2023: −25.03M USDNet income, FY2024: 35.46M USDNet income, FY2025: 190.29M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 30.26M USD. Revenue FY2022 93.46M USD. Revenue FY2023 241.62M USD. Revenue FY2024 441.54M USD. Revenue FY2025 605.49M USD. Operating income FY2021 −39.43M USD. Operating income FY2022 −31.44M USD. Operating income FY2023 −28.73M USD. Operating income FY2024 37.5M USD. Operating income FY2025 108.58M USD. Net income FY2021 −44.22M USD. Net income FY2022 −36.23M USD. Net income FY2023 −25.03M USD. Net income FY2024 35.46M USD. Net income FY2025 190.29M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue605.49M USD441.54M USD241.62M USD93.46M USD30.26M USD
Cost of goods sold242.69M USD179.46M USD87.53M USD28.19M USD9.1M USD
Gross profit362.81M USD262.08M USD154.09M USD65.27M USD21.16M USD
Research and development69.06M USD55.97M USD63.27M USD26.81M USD22.3M USD
Selling, general, and administrative185.17M USD168.62M USD119.55M USD69.9M USD38.28M USD
Operating expenses254.22M USD224.59M USD182.82M USD96.71M USD60.59M USD
Interest income——12.5M USD900K USD—
Interest expense13.78M USD14.41M USD10.79M USD3.73M USD3.87M USD
Depreciation and amortization27.19M USD19.76M USD8.18M USD3.48M USD1.82M USD
Operating income108.58M USD37.5M USD−28.73M USD−31.44M USD−39.43M USD
Net income190.29M USD35.46M USD−25.03M USD−36.23M USD−44.22M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+159.73%
11 comparable reports
Latest EPS result
0.44
Estimate 0.5 · Miss by 11.20%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.980.710.430.16Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.19, estimate 0.22, surprise -13.64%, Miss. Q2 2025, reported May 8, 2025: actual 0.7, estimate 0.29, surprise +141.38%, Beat. Q3 2025, reported Jul 30, 2025: actual 0.92, estimate 0.48, surprise +91.67%, Beat. Q4 2025, reported Oct 29, 2025: actual 0.66, estimate 0.37, surprise +78.38%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.57, estimate 0.41, surprise +39.02%, Beat. Q2 2026, reported May 5, 2026: actual 0.3, estimate 0.62, surprise -51.61%, Miss. Q3 2026, reported Aug 4, 2026: actual 0.44, estimate 0.496, surprise -11.20%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.32, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates197.55M165.66M133.78M101.89MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 121.62M USD, estimate 109.49M USD, surprise +11.08%, Beat. Q2 2025, reported May 8, 2025: actual 143.54M USD, estimate 123.39M USD, surprise +16.32%, Beat. Q3 2025, reported Jul 30, 2025: actual 157.37M USD, estimate 141.62M USD, surprise +11.12%, Beat. Q4 2025, reported Oct 29, 2025: actual 143.82M USD, estimate 155.41M USD, surprise -7.46%, Miss. Q1 2026, reported Feb 24, 2026: actual 160.76M USD, estimate 155.39M USD, surprise +3.46%, Beat. Q2 2026, reported May 5, 2026: actual 173.93M USD, estimate 174.44M USD, surprise -0.29%, Miss. Q3 2026, reported Aug 4, 2026: actual 189.95M USD, estimate 184M USD, surprise +3.23%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 177.03M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$96.86

2.21% upside
Past 12 months12-month forecastHigh $122Average $96.86Low $65.00

Rating distribution

13 ratings
Strong buy00%
Buy969%
Hold431%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
UBSmaintainNeutral

TMDX news

defenseworld.net

30,456 Shares in TransMedics Group, Inc. $TMDX Acquired by Emerald Investment Advisers LLC

Emerald Investment Advisers LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ: TMDX) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.…

Read source
prnewswire.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

NEW YORK, Aug. 21, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ:…

Read source
fool.com

Breakfast News: Week in Review

Moderna jumped 177% on a cancer-vaccine first, plus retail's reversal

Read source
newsfilecorp.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of…

Read source
prnewswire.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

NEW YORK, Aug. 18, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ:…

Read source
fool.com

Breakfast News: Alphabet Goes Shopping for Data

GOOG buys data to aid AI models, Tesla gets closer to formal Cybercab launch, and more

Read source

TMDX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TMDX

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
185.79M
Weight
0.16%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
79.79M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
79.75M
Weight
0.10%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
57.75M
Weight
0.03%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
33.35M
Weight
0.07%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Invesco S&P SmallCap Momentum ETF logoInvesco S&P SmallCap Momentum ETFXSMO
Market value
30.69M
Weight
1.02%
AUM
3.04B USD
Expense ratio
0.36%
Price / 1D
$86.05+0.54%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
30.44M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
29.49M
Weight
0.17%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%

Continue in GoAI

Research TMDX

research.disclaimer